Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cedazuridine/decitabine - Astex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Cedazuridine/decitabine - Astex Pharmaceuticals

Alternative Names: ASTX-727; ASTX-727-LD; ASTX727-10; Cedazuridine/Decitabine; Decitabine/cedazuridine; Decitabine/E7727; E-7727/decitabine; Inaqovi; INQOVI; Oral C-DEC

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Pharmaceuticals; National Cancer Institute (USA)
  • Developer Astex Pharmaceuticals; Otsuka Pharmaceutical; Taiho Oncology; Taiho Pharma Canada
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Fluorinated hydrocarbons; Pyrimidine nucleosides; Ribonucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Registered Acute myeloid leukaemia
  • Phase I/II Myeloproliferative disorders
  • No development reported Breast cancer; Glioma; Solid tumours

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Glioma(Recurrent) in USA (PO)
  • 14 Mar 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top